Brain natriuretic peptide

From Wikipedia, the free encyclopedia

Natriuretic peptide precursor B
Identifiers
Symbol(s)	NPPB; BNP
External IDs	OMIM: 600295 HomoloGene: 81698
Gene ontology Molecular Function: • diuretic hormone activity Cellular Component: • extracellular region • extracellular space Biological Process: • cell surface receptor linked signal transduction • fluid secretion • blood pressure regulation • negative regulation of angiogenesis • diuresis • natriuresis • negative regulation of cell growth • regulation of vasodilation • regulation of vascular permeability • regulation of blood vessel size
RNA expression pattern
More reference expression data
Orthologs
	Human	Mouse
Entrez	4879	n/a
Ensembl	ENSG00000120937	n/a
Uniprot	P16860	n/a
Refseq	NM_002521 (mRNA) NP_002512 (protein)	n/a (mRNA) n/a (protein)
Location	Chr 1: 11.84 - 11.84 Mb	n/a
Pubmed search	[1]	n/a

Brain natriuretic peptide (BNP), also known as B-type natriuretic peptide (also BNP) or GC-B, is a 32 amino acid polypeptide secreted by the ventricles of the heart in response to excessive stretching of myocytes (heart muscles cells) in the ventricles. At the time of release, a co-secreted 76 amino acid N-terminal fragment (NT-proBNP) is also released with BNP. BNP binds to and activates NPRA in a similar fashion to atrial natriuretic peptide (ANP) but with 10-fold lower affinity. The biological half-life of BNP, however, is twice as long as that of ANP. Both ANP and BNP have limited ability to bind and activate NPRB.

Brain natriuretic peptide was originally identified in extracts of porcine brain, but in humans it is produced mainly in the cardiac ventricles.

Physiologic actions of BNP and ANP include decrease in systemic vascular resistance and central venous pressure as well as an increase in natriuresis. Thus, the resulting effect of these peptides is a increase in cardiac output and a decrease in blood volume.

Contents 1 Clinical significance 2 References 3 Further reading 4 External links

[edit] Clinical significance

Tests showing raised levels of BNP or NT-proBNP in the blood are used as a diagnosis of heart failure and may be useful to establish prognosis in heart failure, as both markers are typically higher in patients with worse outcome.^[1]

Both BNP and NT-proBNP have been approved as a marker for acute congestive heart failure (CHF). The plasma concentrations of both BNP are increased in patients with asymptomatic and symptomatic left ventricular dysfunction.

There is no level of BNP that perfectly separates patients with and without heart failure ^[2]:

BNP < 100 pg per milliliter

• sensitivity = 90%
• specificity = 76%

BNP < 50 pg per milliliter

• sensitivity = 97%
• specificity = 62%

For patients with CHF, values will generally be above 100 pg per milliliter; however, a more conservative interpretation of the BNP is that normal values are less than 50 pg per milliliter in order to achieve adequate sensitivity. There is a diagnostic 'gray area', often defined as between 100 and 500, for which the test is considered inconclusive. Values above 500 are generally considered to be positive.

BNP can also be elevated in renal failure^{[citation needed]} (as BNP is excreted renally) and it can be decreased in obesity.^{[citation needed]}

BNP is also marketed as nesiritide for the treatment of acute decompensated congestive heart failure ^[3].

[edit] References

[edit] Further reading

[edit] External links

• MeSH Brain+Natriuretic+Peptide